FDA Panel Rejects AstraZeneca Breast Cancer Drug
AstraZeneca stock declined following an FDA panel vote against a new cancer drug. An advisory panel voted 6-3 against AstraZeneca's oral drug camizestrant intended for specific breast cancer tumors. The panel cited concerns regarding the clinical trial design during the vote.
Topics
Developing
- 863d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 863d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 863d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 863d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Mastodon
“AstraZeneca stock falls after FDA panel votes against new cancer drug”
Mastodon
“An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca’s oral drug camizestrant intended for a type of breast cancer tumor, citing concerns around trial design.”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade